Lymphoma

Although Hodgkin lymphoma is a highly curable form of pediatric cancer, treatment often results in life-threatening or debilitating long-term adverse effects.

Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have moved into early-phase clinical testing with the hope that they will offer many advantages over autologous regimens.

The FDA cleared an investigational new drug application for ADI-001, a an allogeneic chimeric antigen receptor gamma-delta T-cell therapy for the treatment of relapsed or refractory non-Hodgkin lymphoma.

CTX110 exhibited clinical activity among patients with advanced B-cell lymphoma, according to topline data from a phase 1 dose-escalation trial released by the agent’s manufacturer.

The University of Texas MD Anderson Cancer Center announced a new commercial development partnership with San Francisco-based biopharmaceutical company Allogene Therapeutics.

The FDA expanded the approval of pembrolizumab for treatment of classical Hodgkin lymphoma, according to the agent’s manufacturer.

Cardiovascular toxicity associated with chimeric antigen receptor T-cell therapy is both limited and reversible among high-risk children and young adults with acute lymphoblastic leukemia, according to results of a phase 1 clinical trial.

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.

Black and Hispanic patients with cancer demonstrated a higher risk for COVID-19 infection than their white counterparts, according to results of a study presented during ASCO Quality Care Symposium.

A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.